This SR highlights the lack of long-term RCTs reporting final height data and other important qualitative outcomes , such as quality of life .
ABSTRACT Genotropin ( somatropin ) is licensed for the treatment of children with growth hormone deficiency , Prader-Willi syndrome , Turner syndrome , chronic renal insufficiency and in children born small for gestational age .
This systematic review ( SR ) evaluated the clinical efficacy and effectiveness of Genotropin in these conditions to inform a NICE Technology Appraisal of growth hormone for the treatment of growth failure in children .
A Randomised Study of Two Doses of Biosynthetic Human Growth Hormone on Final Height of Pubertal Children with Growth Hormone Deficiency
Aims : To determine the effectiveness of different doses of r-hGH therapy during puberty in children with growth hormone deficiency ( GHD ) . Methods : R and omized controlled trial of different doses of r-hGH therapy administered during puberty in 49 children with GHD . The patients were allocated r and omly using a r and om number table to one of two groups : group 1 ( 15 IU/m2/week ) or group 2 ( 30 IU/m2/week ) . Patients were included if they had received r-hGH daily at a dose of 15 IU/m2/week ( 0.7 mg/m2/day ) for at least 1 year before r and omization . Results : Height increase st and ard deviation scores ( SDS ) were similar between the two groups ( group 1 : 1.1 ; group 2 : 1.2 ; p = 0.81 ) . Conclusion : A higher dose of r-hGH administered during puberty does not appear to have a significant effect on final height of children with GH deficiency . Altering pubertal tempo or intensifying prepubertal r-hGH therapy may be a more promising approach to improving final height in children with GH deficiency
This SR highlights the lack of long-term RCTs reporting final height data and other important qualitative outcomes , such as quality of life .
ABSTRACT Genotropin ( somatropin ) is licensed for the treatment of children with growth hormone deficiency , Prader-Willi syndrome , Turner syndrome , chronic renal insufficiency and in children born small for gestational age .
This systematic review ( SR ) evaluated the clinical efficacy and effectiveness of Genotropin in these conditions to inform a NICE Technology Appraisal of growth hormone for the treatment of growth failure in children .